Frontiers in Cellular Neuroscience, 2020 Post-stroke inflammation is almost involved in the whole process of stroke pathogenesis, which serves as a prime target for developing new stroke therapies. Despite known sex differences in the incidence and outcome of stroke, few preclinical or clinical
Jian Chen +19 more
doaj +1 more source
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. [PDF]
PLoS ONE, 2014 AIM OF THE STUDY:To evaluate the frequency of MRE11/RAD50/NBS1 (MRN)-complex loss of protein expression in endometrial cancers (EC) and to determine whether loss of MRE11 renders the cancer cells sensitive to Poly(ADP-ribose) polymerase (PARP)-inhibitory
Romana Koppensteiner +11 more
doaj +1 more source
Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods [PDF]
PeerJ, 2020 Background Research has shown that Poly-ADP-ribose polymerases 1 (PARP-1) is a potential therapeutic target in the clinical treatment of breast cancer.
Hongye Hu +3 more
doaj +2 more sources
A preliminary study on the synthetic lethal effect of berberine and olaparib on pancreatic cancer cells and its mechanism [PDF]
E3S Web of Conferences, 2021 Pancreatic cancer is a kind of malignant tumor with high mortality rate. Early operation and late chemoradiotherapy are the treatment criteria, but the prognosis is still poor.
Zhang Chengyong +9 more
doaj +1 more source
Effects of alcohol and PARP inhibition on RNA ribosomal engagement in cortical excitatory neurons
Frontiers in Molecular Neuroscience, 2023 We report on the effects of ethanol (EtOH) and Poly (ADP-ribose) polymerase (PARP) inhibition on RNA ribosomal engagement, as a proxy for protein translation, in prefrontal cortical (PFC) pyramidal neurons.
Harish R. Krishnan +10 more
doaj +1 more source
PARP Inhibitors in Prostate Cancer [PDF]
Anticancer Research, 2021 Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in ...
Kabir, Grewal +2 more
openaire +2 more sources
Poly(ADP-Ribose) Polymerase (PARP) signaling of DNA damage induced by Topoisomerase 1 (TOP1) inhibition in carcinoma cells: chemotherapeutic implications of PARP and TOP1 inhibitors. [PDF]
, 2010 Una nuova strategia molecolare che incrementa l’azione antitumorale degli inibitori della Topoisomerasi 1 (TOP1) si basa sull’utilizzo di inibitori delle poli(ADP-ribosio) polimerasi (PARP).
D'Onofrio, Giovanna
core +1 more source
PARP Inhibitors for Chemoprevention—Letter [PDF]
Cancer Prevention Research, 2014 We read with great optimism To and colleagues' ([1][1]) article about PARP inhibitors as effective chemopreventive strategy for treating homologous repair (HR)–deficient tumors. Their overarching conclusion stated in the discussion is that “…synthetic lethality (i.e., PARP inhibitor ...
Saswati N, Chand +8 more
openaire +2 more sources
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Therapeutic Advances in Medical Oncology, 2017 Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer.
Tarra Evans, Ursula Matulonis
doaj +1 more source
Cells, 2020 The role and therapeutic promise of poly-ADP ribose polymerase (PARP) inhibitors in anticancer chemotherapy are increasingly being explored, particularly in adjuvant or maintenance therapy, considering their low efficacy as monotherapy agents and their ...
Shiue-Wei Lai +6 more
doaj +1 more source